New, Improved Cytogenetics Arrays from OGT

Oxford Gene Technology (OGT), the pioneer of microarray-based technologies, has launched the latest versions of its CytoSure™ family of high resolution oligonucleotide arrays, offering even more coverage than before for cytogenetic syndromes and accurate whole genome aberration detection. The Syndrome Plus v2 and Chromosome X High Density arrays have been developed in close collaboration with leading cytogeneticists for a complete, cost-effective array solution.

The CytoSure Syndrome Plus v2 array covers over 200 known cytogenetic syndrome regions, including 410 genes associated with autism, mental retardation, heart and eye diseases, with one probe every 3 kb. The array also offers extensive coverage of the whole genome, including subtelomeric regions and recombinant hotspots, with one probe every 40 kb. The Chromosome X High Density array has a probe density of one probe every 2 kb to target genes on the X chromosome, including exons, miRNAs, rRNAs and snRNAs. Both arrays are available in 2x105k format.

Also available is analysis software that allows easier interpretation of results with data exchange for comprehensive, state-of-the-art cytogenetic profiling.

Spencer Howell, Director of Cytogenetics at OGT said: "I am delighted to announce the release of the second generation of CytoSure oligonucleotide arrays from OGT. The newly designed arrays, along with our expanding 'Complete Solution' approach, further underlines our commitment to provide aCGH analysis in cytogenetics laboratories worldwide."

OGT offers total support from sample to result, as well as comprehensive training to users of CytoSure arrays.